Codiak BioSciences, Inc. (CDAK)
| Market Cap | 26.52M |
| Revenue (ttm) | 34.07M |
| Net Income (ttm) | -17.42M |
| Shares Out | 36.83M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,441 |
| Open | 0.700 |
| Previous Close | 0.710 |
| Day's Range | 0.690 - 0.720 |
| 52-Week Range | 0.300 - 7.150 |
| Beta | 3.46 |
| Analysts | Buy |
| Price Target | 5.92 (+722.34%) |
| Earnings Date | Mar 9, 2023 |
About CDAK
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vacci... [Read more]
Financial Performance
In 2021, CDAK's revenue was $22.94 million, an increase of 686.79% compared to the previous year's $2.92 million. Losses were -$37.16 million, -63.75% less than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CDAK stock is "Buy." The 12-month stock price forecast is $5.92, which is an increase of 722.34% from the latest price.
News
ATUM Announces Leap-In Transposase® Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based Therapeutics
NEWARK, Calif.--(BUSINESS WIRE)--ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In Transposase® tec...
Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a ne...
Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting can...
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...
Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress
– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated during 1H 2023 –
All You Need to Know About Codiak BioSciences, Inc. (CDAK) Rating Upgrade to Strong Buy
Codiak BioSciences, Inc. (CDAK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ter...
Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses
– Data support advancement of Codiak's engineered exosome bivalent vaccine candidate toward IND-enabling studies –
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –
Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeu...
Codiak Announces Proposed Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeu...
Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring
– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma –
Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc...
Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress
– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023 –
Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a ne...
Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022
CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a ne...
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine
OSLO, Norway and CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences (NASDAQ: CDAK) today announced the latest funding...
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. In an open...
Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™
– Codiak's engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window –
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak's engEx® Platform to enter clinical development
Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy
Engineering exosomes to encapsulate AAV results in increased yield, resists antibody neutralization in vitro and retains transduction ability Engineering exosomes to encapsulate AAV results in increas...
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress
– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 –
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
– Experienced oncology drug developer with more than two decades advancing treatments for solid tumors and hematologic malignancies joins Codiak leadership – – Experienced oncology drug developer with...
Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine
– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo –
Codiak's exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells
– New preclinical data presented at AACR Annual Meeting 2022 –